Related Experiment Video
Updated: Jun 16, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Oral insulin: the rationale for this approach and current developments.
1Oramed Pharmaceuticals, Jerusalem, Israel. ehud@oramed.com
Journal of Diabetes Science and Technology
|February 11, 2010
Summary
Developing oral insulin could improve diabetes management by enhancing patient adherence and mimicking natural insulin delivery. This review explores the physiological benefits and technological advancements for oral insulin dosage forms.
Area of Science:
- Pharmacology
- Biotechnology
- Endocrinology
Background:
- Insulin is a crucial hypoglycemic agent for diabetes treatment.
- Oral insulin offers potential benefits for patient compliance and physiological advantages by mimicking natural insulin secretion and absorption.
- Direct liver targeting via the portal vein is a key physiological advantage.
Purpose of the Study:
- To review the physiological rationale and advantages of oral insulin.
- To explore current technologies enabling oral insulin delivery.
- To assess the potential of oral insulin dosage forms in diabetes management.
Main Methods:
- Literature review of physiological principles for oral insulin.
- Analysis of technological platforms for polypeptide and protein delivery.
- Examination of advancements in gastrointestinal absorption technologies for insulin.
Main Results:
- Several technological platforms exist to protect insulin from degradation and enhance absorption.
- These technologies aim to overcome enzymatic hydrolysis and facilitate epithelial transport.
- The development of oral insulin dosage forms is progressing.
Conclusions:
- Oral insulin holds significant promise for improving diabetes care through enhanced adherence and targeted delivery.
- Technological innovations are crucial for overcoming the challenges of oral insulin administration.
- Further development of oral insulin dosage forms could revolutionize diabetes treatment.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...